{'52WeekChange': None,
 'SandP52WeekChange': None,
 'address1': '4000 Shoreline Court',
 'address2': 'Suite 300',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.81,
 'askSize': 1200,
 'averageDailyVolume10Day': 285462,
 'averageVolume': 880022,
 'averageVolume10days': 285462,
 'beta': 0.126598,
 'beta3Year': None,
 'bid': 4.79,
 'bidSize': 2200,
 'bookValue': 3.213,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.89,
 'dayLow': 4.76,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -1.721,
 'enterpriseToRevenue': None,
 'enterpriseValue': 65673044,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 5.2405715,
 'fiftyTwoWeekHigh': 9.79,
 'fiftyTwoWeekLow': 2.18,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 25959529,
 'forwardEps': -1.3,
 'forwardPE': -3.6846154,
 'fromCurrency': None,
 'fullTimeEmployees': 40,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.34182,
 'heldPercentInstitutions': 0.35559,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kezarlifesciences.com',
 'longBusinessSummary': 'Kezar Life Sciences, Inc., a clinical-stage '
                        'biotechnology company, engages in the discovery and '
                        'development of novel small molecule therapeutics to '
                        'treat unmet needs in autoimmunity and cancer in the '
                        "United States. The company's lead product candidate "
                        'is KZR-616, a selective immunoproteasome inhibitor '
                        'that is in Phase 2 clinical trials across five '
                        'autoimmune indications, including lupus nephritis, '
                        'autoimmune hemolytic anemia, immune thrombocytopenia, '
                        'dermatomyositis, and polymyositis; and Phase 1b/2 '
                        'clinical trials in systemic lupus erythematosus and '
                        'lupus nephritis. Its preclinical products include '
                        'KZR-616, a selective immunoproteasome inhibitor for '
                        'the treatment of various autoimmune disease '
                        'indications; and KZR-TBD for the treatment of '
                        'oncology and autoimmunity. The company was founded in '
                        '2015 and is headquartered in South San Francisco, '
                        'California.',
 'longName': 'Kezar Life Sciences, Inc.',
 'market': 'us_market',
 'marketCap': 219230640,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_304157325',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -37457000,
 'nextFiscalYearEnd': 1640908800,
 'open': 4.85,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 822 5600',
 'previousClose': 4.88,
 'priceHint': 4,
 'priceToBook': 1.4908185,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.89,
 'regularMarketDayLow': 4.76,
 'regularMarketOpen': 4.85,
 'regularMarketPreviousClose': 4.88,
 'regularMarketPrice': 4.85,
 'regularMarketVolume': 183400,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 45768400,
 'sharesPercentSharesOut': 0.0298,
 'sharesShort': 1363706,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 299939,
 'shortName': 'Kezar Life Sciences, Inc.',
 'shortPercentOfFloat': 0.0359,
 'shortRatio': 0.69,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'KZR',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.662,
 'twoHundredDayAverage': 4.6323743,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': 'a58d540c-0082-3b09-9235-096cecf4e362',
 'volume': 183400,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kezarlifesciences.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}